Received Apr 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 9K74F | — |
Pediatric dose to an adult patient; Pediatric dose to an adult patient; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 20-year-old female patient who received HBV (Engerix B pediatric) (batch number 9K74F, expiry date 27-OCT-2025) for prophylaxis. On 06-MAR-2025, the patient received Engerix B pediatric. On 06-MAR-2025, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: Pediatric dose to an adult patient) and underdose (Verbatim: Pediatric dose to an adult patient). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 09-APR-2025 A 20-year-old patient was given Engerix B, the birth to 19 year old Engerix-B. The Vaccine Administration Facility is the same as Primary Reporter The healthcare professional confirmed that it was the Engerix-B vaccine, and that the patient received the pediatric dose which led to adult use of a child product and underdose.